Sanofi S.A., FR0000120578

RBC cuts target for Sanofi stock to EUR 75 before results

Published on 10/23/2026 at 10:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC cut the target from EUR 80 to EUR 75 on October 16, 2026. Sanofi stock costs EUR 74.25 on October 23, 2026.

Targets and dates shape the setup

RBC lowered its Sanofi target from EUR 80 to EUR 75 on October 16, 2026.
Sanofi scheduled third-quarter 2026 results for October 30, 2026.
Sanofi stock was trading at EUR 74.25 at 10:47 a.m. CEST at Lang & Schwarz on October 23, 2026.

Bold pop-art comic illustration of a gloved hand holding a glowing cyan syringe with radial energy lines on a violet halftone dot background — Sanofi FR0000120578 bold pop-art comic illustration of gloved hand holding glowing syringe with violet-cyan energy, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) stock was trading at EUR 74.25 at Lang & Schwarz on October 23, 2026 at 10:47 a.m. CEST. The latest analyst action came from RBC, which cut its target from EUR 80 to EUR 75 on October 16, 2026, while keeping a Sector Perform rating, according to t-online.

Why did RBC trim the target?

RBC analyst Trung Huynh said the strength of Dupixent may not offset pressure in other parts of Sanofi's business. The note also said market expectations for revenue and earnings could be too high, giving the target reduction a clear counter-factor before the next results.

The new EUR 75 target stands only EUR 0.75 above the Lang & Schwarz price on October 23, 2026. That narrow gap makes the October 30 reporting date particularly relevant for the stock's next valuation signal.

Three dated Sanofi developments

Sanofi published its Q3 2026 aide-memoire on October 6, 2026, and stated that third-quarter results would be released on October 30, 2026, in a Sanofi release. RBC then lowered its target from EUR 80 to EUR 75 on October 16, 2026. On October 19, 2026, Sanofi said it had broken ground on a new insulin manufacturing facility in Germany, according to its investor-relations page.

What dates matter next?

The next substantiated date is October 30, 2026, when Sanofi will publish third-quarter results and host a management webcast, according to Sanofi. The company also lists the Jefferies Global Healthcare Conference in London for November 17, 2026, with Vaccines executive Thomas Triomphe scheduled to speak.

Stock price and investor view

For investors, the central test is whether Sanofi's third-quarter update can challenge the cautious assumptions behind RBC's EUR 75 target. The October 19 insulin investment adds an operating milestone, while the October 30 results provide the next hard checkpoint for revenue, earnings and pipeline execution.

Sanofi was trading at EUR 74.25 at Lang & Schwarz on October 23, 2026 at 10:47 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.